Aims: Improved treatments for prostate cancer are critically needed in order to overcome metastasis and lethal recurrence. Intravenously administered gene therapy would be an attractive anti-cancer treatment strategy, however the lack of suitable carrier systems able to selectively deliver therapeutic genes to tumors has so far limited this investigation. Given that transferrin receptors are overexpressed on prostate cancer cells, the purpose of this study is to determine whether transferrinbearing dendriplex encoding TNF±, TRAIL and IL-12 would suppress the growth of prostate cancer cell lines in vitro and in vivo.
INTRODUCTION
Prostate cancer is one of the most commonly diagnosed malignancies in men and remains the second leading cause of cancer-related deaths in the United States and the European Union. Although radiation therapy, chemotherapy, radical prostatectomy and cryoablation can be efficacious therapies for localized tumors, there is still no effective treatment modality for patients with recurrent or metastatic disease [1] . New treatment approaches are therefore critically needed for these patients.
Among novel experimental strategies, gene therapy holds great promise for the treatment of prostate cancer. The identification of the genetic mutations involved in this disease has led to the development of a wide panel of highly diverse, rapidly evolving gene therapy approaches, such as corrective gene therapy, suicide gene therapy, apoptosis-inducing gene therapy and immunomodulation therapy [1] . These approaches have already shown promise for in situ use. For example, in a phase I/II clinical trial, the in situ delivery of an adenoviral vector delivery of the Herpes Simplex Virus thymidine kinase gene followed by the pro-drug ganciclovir resulted in apoptosis of prostate cancer cells and immune cell activation [2, 3] .
However, the use of gene therapy is currently limited by the lack of delivery systems able to selectively deliver the therapeutic genes to the tumors by intravenous administration, without secondary effects to normal tissues. In order to overcome this problem, we recently demonstrated that the conjugation of transferrin (whose receptors are abundantly expressed on cancer cells) to generation 3-diaminobutyric polypropylenimine (DAB) dendrimer led to gene expression principally in the tumors following intravenous administration [4] . As a result, the intravenous administration of DAB-Tf dendrimer complexed to the Tumor Necrosis Factor (TNF±) expression plasmid led to tumor suppression for 90% of the A431 epidermoid carcinoma tumors, with long-term survival of the mice.
Building on these promising results, we have focused on investigating if this delivery system carrying plasmids encoding for TNF±, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or interleukin-12 (IL-12), could lead to therapeutic effects on prostate cancer following intravenous administration.
TRAIL, a member of the TNF family of cytokines, is particularly promising in the development of anti-cancer therapeutics, as it preferentially induces apoptosis of cancer cells whilst sparing normal cells [5] . Its binding to death receptors DR4 and DR5 leads to recruitment of Fas-associated death domain, resulting in tumor cell death via caspase-dependent apoptotic pathways [5] . As it has a short biological halflife and is rapidly cleared from the circulation after intravenous administration [6] , new delivery strategies are particularly needed to improve its therapeutic potency.
Another cytokine, IL-12, has been shown to be efficacious in the induction of potent antitumor immunity [7] . IL-12 has multiple effects on B cells, T cells and natural killer cells and is also a major regulator of Th1 cell differentiation. In animal melanoma models, the administration of IL-12 plasmid resulted in tumor growth inhibition in addition to regression of established tumors [8] . However, the intravenous use of IL-12 is hampered by its potential side effects [9] , thus emphasizing the need of tumorspecific delivery.
The objectives of this study were therefore to investigate if transferrin-bearing DAB dendrimer complexed with TNF±, TRAIL or IL-12 expression plasmids had a therapeutic effect on prostate cancer cells in vitro and in vivo after intravenous administration.
MATERIALS & METHODS

Cell lines and reagents
Generation 3-diaminobutyric polypropylenimine dendrimer (DAB), iron-saturated human holo-transferrin, dimethylsuberimidate and the other reagents were from Sigma Aldrich (Poole, UK). The expression plasmids encoding ² -galactosidase (pCMVsport ² -galactosidase) and TNF± (pORF9-mTNF±) were purchased respectively from Invitrogen (Paisley, UK) and InvivoGen (San Diego, CA), while the expression plasmids encoding TRAIL (pORF9-mTRAIL) and IL-12 (pORF-mIL12) came from Source BioScience (Nottingham, UK). These plasmids were purified using an Endotoxin-free Giga Plasmid Kit (Qiagen, Hilden, Germany). Label IT ® Cy3
Nucleic Acid Labeling kit was purchased from Cambridge Biosciences (Cambridge, UK 
Preparation of transferrin-bearing polypropylenimine dendrimer
Generation 3-diaminobutyric polypropylenimine dendrimer (DAB, 24 mg) was conjugated to transferrin (Tf, 6 mg) by cross-linking with dimethylsuberimidate (DMSI, 12 mg) in triethanolamine HCl buffer (pH 7.4, 2 mL), as previously described [4, 10] . The conjugation reaction took place at 25 o C for 2 h whilst stirring. DAB-Tf dendrimer was then purified by size exclusion chromatography using a Sephadex G75 column, freeze-dried, before having its identity confirmed by 1 H NMR spectroscopy, using a Jeol Oxford NMR AS 400 spectrometer [4] .
In vitro studies
Cell culture 
and penicillin-streptomycin (0.5% (v/v) were added to both media. In addition, RPMI medium was also supplemented with 10 mM HEPES (5 mL) and 1 mM sodium pyruvate (5 mL).
Cellular uptake of DNA
Plasmid DNA encoding ² -galactosidase was labeled with the fluorescent probe Cy3 using a Label IT ® Cy3 Nucleic Acid Labeling kit, as described by the manufacturer.
PC-3, DU145 and LNCaP cells were seeded on coverslips in 6-well plates (10 4 cells/ well) and grown at 37 o C for 24 h. They were then incubated with Cy3-labeled DNA (2.5 µg DNA / well) complexed by mixing to DAB-Tf and DAB at their optimal dendrimer: DNA weight ratios (leading to complete DNA condensation and highest transfection) respectively of 10:1 for DAB-Tf and 5:1 for DAB [10, 11] . Control slides were treated with naked DNA. Following 24 h treatment, the cells were then washed three times with PBS and fixed with methanol for 10 min. DAPI was then used to stain the nuclei and the cells were examined using a Leica TCS SP5 confocal microscope. DAPI was excited with the 405 nm laser line (bandwidth: 415-491nm),
whereas Cy3 was excited with the 543 nm laser line (bandwidth: 550-620 nm). Cy3-related fluorescence intensity was then quantified in each of the confocal microscopy pictures by using Adobe Photoshop Elements software. Results were expressed as fluorescence intensity (in arbitrary units) per cell.
In vitro transfection
Transfection efficacy of the plasmid DNA encoding ² -galactosidase and carried by DAB-Tf dendrimer was evaluated by a ² -galactosidase transfection assay. Bioluminescence imaging using an IVIS Spectrum (Caliper Life Sciences, Hopkinton, MA) was also used to monitor the therapeutic efficacy of the treatments. To this end, mice bearing subcutaneous PC-3M-luc-C6 tumors were intravenously injected with treatments as described above. Ten minutes before imaging, they were intraperitoneally injected with the luciferase substrate D-luciferin (150 mg/kg body weight), before being anaesthetized by isoflurane inhalation on Days 1, 3, 5, 7, 9 of the experiment. The light emitted from the bioluminescent tumors was detected for 2 min using Living Image ® software and displayed as a pseudo-color overlay onto a gray scale image of the animal. Identical illumination settings were used for acquiring all images [12] .
Statistical Analysis
Results were expressed as means ± standard error of the mean (S.E.M). Statistical significance was assessed by one-way analysis of variance (ANOVA) and Bonferroni multiple comparison post-test (GraphPad Prism software). P values lower than 0.05
were considered statistically different.
RESULTS
Cellular uptake of DNA
Confocal microscopy experiments confirmed that Cy3-labelled DNA was taken up by PC-3, DU145 and LNCaP cells ( Figure 1 ). The fluorescently-labeled DNA was found to be disseminated in the cytoplasm following treatment with DAB-Tf and DAB dendriplexes in the three tested cell lines. However, the DNA uptake appeared to be much more pronounced after treatment with Tf-bearing dendriplex than with the non- 
In vitro transfection
Treatment with DAB-Tf dendriplex led to an increase in gene expression on both PC-3 and LNCaP cells ( Figure 2 ). On PC-3 cells, gene expression following treatment with DAB-Tf dendriplex (2.69x10 -3 ± 0.09x10 -3 U/mL) was 1.3-fold higher than with unconjugated DAB dendriplex (2.08x10 -3 ± 0.09x10 -3 U/mL). Similarly, it was slightly higher following treatment with DAB-Tf dendriplex (1.77x10 -3 ± 0.11x10 -3 U/mL) than that observed with DAB dendriplex (1.53x10 -3 ± 0.05x10 -3 U/mL) on LNCaP cells.
However, there was no significant difference between gene expression following treatment with DAB-Tf dendriplex and DAB dendriplex on DU145 cells (1.47x10 -3 ± 0.10x10 -3 U/mL and 1.29x10 -3 ± 0.11x10 -3 U/mL respectively). Treatment with control dendrimer and naked DNA only resulted in weak levels of gene expression, as expected.
In vitro anti-proliferative activity
DAB-Tf complexed to TNF±, TRAIL and IL-12 expression plasmids significantly enhanced the in vitro anti-proliferative efficacy on the three prostate cancer cell lines when compared to the unconjugated dendriplex ( Overall, the most efficacious treatment observed in this in vitro study was DAB-Tf dendriplex expressing TNF± on PC-3 cells. By contrast, uncomplexed DAB-Tf, DAB and naked DNA did not exert any cytotoxicity to the cells at the tested concentrations, thus demonstrating that 1) DAB-Tf and DAB dendrimers were safe for the cells in the range of concentrations used in our experiments and 2) that a tumor-targeted delivery system is needed for the effective delivery, transfection and subsequently efficacy of the therapeutic DNA on prostate cancer cells.
In vivo study
The intravenous administration of DAB-Tf dendriplex encoding TNF± resulted in PC- No apparent sign of toxicity or significant weight loss were observed, suggesting that all treatments were well tolerated by the mice (Figures 3 and 4) .
DISCUSSION
The use of gene therapy for the treatment of recurrent prostate cancer and its metastasis is currently hampered by the lack of safe and efficacious gene delivery systems able to deliver therapeutic genes to their site of action following intravenous administration, without secondary effects to normal tissues. In order to remediate to this problem, we hypothesized that a generation 3-diaminobutyric polypropylenimine Furthermore, generation 3-DAB dendrimer presents the advantage of having 100% protonable nitrogens [15] , making it particularly suitable for binding the negatively charged DNA by electrostatic interactions [16] .
In this study, we successfully demonstrated that the conjugation of Tf on the dendriplexes improved DNA uptake by the three prostate cancer cell lines studied, compared to control dendriplexes and naked DNA treatment. Tf receptor-mediated uptake of DNA and drugs has been extensively studied on numerous cancer cell lines [17] [18] [19] [20] [21] [22] , but rarely on prostate cancers. Although the difference between treatments was less pronounced in our study, our results were in accordance with previous data obtained by Sahoo intravenous administration, while using a viral delivery system rather than a non-viral one, and often in conjunction with other therapeutic modalities, such as radiotherapy [28] , co-administration with oncolytic herpes simplex viruses [29] , with adenoviral vector-mediated Herpes Simplex Virus / thymidine kinase and ganciclovir [30] , or in addition with the drug mifepristone [31] . For example, the intratumoral administration of an adenoviral vector encoding the TRAIL gene under the control of FLT1
promoter, in combination with radiation treatment, was shown to produce significant slowdown of the growth of DU145 tumor xenografts in athymic nude mice [25] . In another work, the intratumoral administration of a recombinant adenovirus expressing IL-12 was shown to significantly slowdown the growth of RM-9 prostate tumors [32] . Similar results were obtained by Saika and colleagues [33] following the intratumor administration of an adenovirus-mediated IL-12 on a 178-2 BMA prostate cancer model. The effects observed in these studies were generally a slowdown of tumor growth, rather than the tumor regression or suppression observed in some instances in our experiments.
In the DU145 xenograft model, the therapeutic effect of DAB-Tf dendriplex encoding TNF± was more pronounced than that obtained with TRAIL and IL-12, contrarily to what was observed in our anti-proliferative assay in vitro. This could be explained by the fact that TNF± exerts its potent cytotoxic effects on tumors in vivo via the death receptor-dependent apoptotic pathway, like TRAIL, but also via its anti-angiogenic effects, believed to be critical for its anti-cancer activity [34, 35] . It actually highlights the limitation of in vitro experiments for predicting the anti-cancer outcome of novel therapeutic systems in vivo.
In this study, we have chosen to use, among other therapeutic agents, a plasmid DNA encoding IL-12. The biological effects of Il-12 encompass stimulation of unspecific immunity, such as via activation of NK cells, and stimulation of specific immunity as mediated by cytotoxic T lymphocytes. In our experiments, we had to use immunodeficient BALB/c mice unable to produce T cells in order for them to grow subcutaneous tumors of human origin. We therefore hypothesize that the therapeutic effect observed could be further improved by using a fully immunocompetent mouse bearing a murine prostate tumor model [36] .
Our previous work, carried out with a therapeutic DNA encoding TNF± on A431 epidermoid carcinoma tumors, demonstrated the tumor targeting capability of Tfbearing DAB dendrimer and led to a more pronounced therapeutic effect than that observed when using prostate tumor models [4] . These results highlight the difficulties encountered for the treatment of prostate tumors, independently of the therapeutic strategy chosen, and explain why so many studies use combinatorial modalities to improve the overall therapeutic effect. In this study, we wanted to evaluate the therapeutic efficacy of Tf-bearing DAB dendriplexes encoding TNF±, TRAIL and IL-12 on prostate tumor models following intravenous administration.
Tumor-targeted TNF± gene therapy was more efficacious than TRAIL and IL-12, leading to tumor regression and even some tumor disappearance. Still, TRAIL and Il-12-mediated gene therapy actually improved the therapeutic efficacy on prostate tumor models, compared to the slowdown of tumor growth generally observed following intratumoral administration of adenovirus-based gene medicines, and this without any combinatorial treatment. In addition, these tumor-targeted systems are intravenously delivered, thereby allowing them to reach metastases as well as primary tumors, which is particularly important for the treatment of prostate tumors.
CONCLUSIONS
In this study, we have demonstrated for the first time that a tumor-targeting, dendrimer-based gene delivery system complexed to a plasmid DNA encoding TNF± and TRAIL can lead to eradication of some prostate tumors after intravenous administration.
In Transferrin-bearing DAB dendriplexes encoding TNF±, TRAIL and IL-12 therefore hold great potential as a novel approach for the gene therapy of prostate cancer and should be further investigated to optimize their therapeutic potential.
FUTURE PERSPECTIVE
While gene therapy has been widely studied in laboratory settings for its therapeutic potential against cancer, little has been done regarding its intravenous, targeted administration to prostate tumors. This is a particularly important issue in the case of this cancer, as there is still no efficacious treatment modality for patients suffering from a recurrent disease or metastasis. In this study, we demonstrated for the first time that the intravenous administration of Tf-bearing DAB dendriplex encoding TNF± resulted in tumor suppression for 60% of PC-3 and 50% of DU145 tumors when using a TNF± encoding plasmid, and for 10% of PC-3 tumors when using a TRAIL encoding plasmid. We therefore hope that this breakthrough will lead to the development of tumor-targeted gene therapy for the treatment of prostate cancer.
In addition, transferrin-bearing DAB dendriplexes encoding TNF±, TRAIL and IL-12
should be further studied to optimize their therapeutic potential against cancer.
EXECUTIVE SUMMARY
Introduction:
• Gene therapy would be an attractive anti-cancer treatment strategy against advanced prostate cancer
• Its use is limited by its failure to reach tumors in a specific way after intravenous administration
In vitro therapeutic efficacy:
• In vitro, transferrin-bearing dendriplex encoding TNF±, TRAIL and IL-12
improved the anti-proliferative efficacy of the therapeutic DNA on PC-3,
DU145 and LNCaP prostate cancer cells
In vivo tumoricidal activity:
• In vivo, the intravenous administration of DAB-Tf dendriplex encoding TNF± resulted in tumor disappearance for 60% of PC-3 and 50% of DU145 tumors.
Treatment with of DAB-Tf dendriplex encoding TRAIL led to tumor disappearance for 10% of PC-3 tumors. Consequently, the survival of the treated mice was increased by 22 days compared to untreated tumors, for both cell lines.
Conclusion:
• Transferrin-bearing DAB dendriplexes encoding TNF±, TRAIL and IL-12 therefore hold great potential as a novel approach for the gene therapy of prostate cancer and should be further investigated to optimize their therapeutic potential.
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